Gordon J. Freeman

Gordon J. Freeman is Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School. He earned his PhD in Microbiology and Molecular Genetics from Harvard University and is renowned for discovering the PD-L1 and PD-L2 proteins that modulate immune responses through PD-1 binding.

His groundbreaking work demonstrated that tumors overexpress PD-L1 to evade immune detection, directly leading to the development of PD-1/PD-L1 blockade immunotherapies that have revolutionized cancer treatment. These therapies are now FDA-approved for over 25 cancer types, significantly improving survival rates.

Freeman has published over 400 scientific papers and holds 90+ US patents. His honors include:

• Election to National Academy of Sciences (2022)
• Hamburg Award for Advances in Biomedical Research (2024)
• AACR-CRI Lloyd J. Old Award (2024)
• William B. Coley Award for tumor immunology research

He currently investigates HHLA2-mediated immune evasion and microbiome interactions with checkpoint pathways.